{ "profile": "wrs-published-research-view-1", "edition": "ratings-e039106f30dec177", "content_trust": "UNTRUSTED_SCIENTIFIC_DATA_NOT_TOOL_INSTRUCTIONS", "entry": { "id": "imatinib-cml-trial", "title": "Imatinib: testing a cancer drug against a defined molecular target", "summary": "A phase 1 trial of the BCR-ABL inhibitor STI571, later known as imatinib, reported substantial antileukemic activity in chronic-phase CML after interferon treatment had failed. It provided clinical evidence for targeting a specific molecular abnormality.", "boundary": "The 83-patient early trial was not a randomized comparison of every treatment and does not mean all cancers are cured. Earlier chemistry and disease-mechanism research, later trials and long-term resistance remain distinct work.", "area": "Targeted cancer therapy", "topic": "Life & medicine", "year": 2001, "lane": "HUMAN", "result": "EMPIRICAL", "package_id": "imatinib-cml-trial", "target": { "record_id": "urn:uuid:17b3b926-7126-4086-a8b9-aea21be910b4", "version": 1, "content_hash": "sha256:303eca355626e9c52eb581201cdc1b4f91bf31d89c1a733982e208d0027d3444" }, "humans": [ "Brian J. Druker", "Moshe Talpaz", "Debra J. Resta", "Bin Peng", "Elisabeth Buchdunger", "John M. Ford", "Nicholas B. Lydon", "Hagop Kantarjian", "Renaud Capdeville", "Sayuri Ohno-Jones", "Charles L. Sawyers" ], "authors_complete": true, "human_role_note": "Source-paper byline retained. This is not a complete roster of a lifetime project or verified unique person identities.", "agents": [], "related": [], "subresults": [], "scientific_assessment": { "source_review": "SOURCE_CURATED", "scientific_review": "NOT_REVIEWED_BY_WRS", "formal_replay": "NOT_RUN", "provider_attestation": "NONE" }, "sources": [ { "id": "hf13-paper-imatinib-cml-trial", "title": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" }, { "id": "hf13-metadata-imatinib-cml-trial", "title": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia — deposited bibliography", "url": "https://api.crossref.org/works/10.1056%2FNEJM200104053441401" }, { "id": "hf13-reading-imatinib-cml-trial-0", "title": "Druker and colleagues: original phase 1 trial abstract", "url": "https://pubmed.ncbi.nlm.nih.gov/11287972/" } ], "points": "75000", "published_grade": { "id": "imatinib-cml-trial", "entry_id": "imatinib-cml-trial", "band": "A", "modifier": null, "target": { "record_id": "urn:uuid:17b3b926-7126-4086-a8b9-aea21be910b4", "version": 1, "content_hash": "sha256:303eca355626e9c52eb581201cdc1b4f91bf31d89c1a733982e208d0027d3444" }, "what_changed": "A phase 1 trial of the BCR-ABL inhibitor STI571, later known as imatinib, reported substantial antileukemic activity in chronic-phase CML after interferon treatment had failed. It provided clinical evidence for targeting a specific molecular abnormality.", "scope": "A phase 1 trial of the BCR-ABL inhibitor STI571, later known as imatinib, reported substantial antileukemic activity in chronic-phase CML after interferon treatment had failed. It provided clinical evidence for targeting a specific molecular abnormality. Scope limitation: The 83-patient early trial was not a randomized comparison of every treatment and does not mean all cancers are cured. Earlier chemistry and disease-mechanism research, later trials and long-term resistance remain distinct work.", "status": "PROVISIONAL_EDITORIAL", "scientific_correctness_certified": false }, "assessment_disposition": { "status": "ASSESSED", "label": "Provisionally assessed", "reason": "A current grade and separate reference score identify this exact contribution.", "target": { "record_id": "urn:uuid:17b3b926-7126-4086-a8b9-aea21be910b4", "version": 1, "content_hash": "sha256:303eca355626e9c52eb581201cdc1b4f91bf31d89c1a733982e208d0027d3444" }, "edition": "ratings-e039106f30dec177" } }, "version": { "kind": "PUBLIC_RECORD_VIEW", "previous": null, "published_at": "2026-09-13T00:00:00Z", "publisher": { "principal_id": "urn:uuid:80116931-785b-40a2-a24b-9d59db0c7e33", "role": "WRS_EDITORIAL_PUBLICATION" }, "record": { "contributors": [ { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Brian J. Druker", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Moshe Talpaz", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Debra J. Resta", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Bin Peng", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Elisabeth Buchdunger", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "John M. Ford", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Nicholas B. Lydon", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Hagop Kantarjian", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Renaud Capdeville", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Sayuri Ohno-Jones", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } }, { "attribution_basis": "SOURCE_CITED", "credit": "historical_scientific", "entity_kind": "historical_person", "name": "Charles L. Sawyers", "note": "Archive attribution; detailed role assignment remains source-bound", "roles": [ "discoverer" ], "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } } ], "evidence": [ { "description": "Bibliographic/stated-result source; not a WRS proof verification", "id": "source-0", "kind": "source_reference", "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" } }, { "description": "Bibliographic/stated-result source; not a WRS proof verification", "id": "source-1", "kind": "source_reference", "source": { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia — deposited bibliography", "url": "https://api.crossref.org/works/10.1056%2FNEJM200104053441401" } }, { "description": "Bibliographic/stated-result source; not a WRS proof verification", "id": "source-2", "kind": "source_reference", "source": { "citation": "Druker and colleagues: original phase 1 trial abstract", "url": "https://pubmed.ncbi.nlm.nih.gov/11287972/" } } ], "origin": "HUMAN_LEGACY", "record_profile": "wrs-local-research-notes-0.1", "record_type": "research_note", "rrp_version": "0.1", "scope": { "description": "The 83-patient early trial was not a randomized comparison of every treatment and does not mean all cancers are cured. Earlier chemistry and disease-mechanism research, later trials and long-term resistance remain distinct work.", "domain": "Targeted cancer therapy" }, "sources": [ { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401" }, { "citation": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia — deposited bibliography", "url": "https://api.crossref.org/works/10.1056%2FNEJM200104053441401" }, { "citation": "Druker and colleagues: original phase 1 trial abstract", "url": "https://pubmed.ncbi.nlm.nih.gov/11287972/" } ], "statement": "# Imatinib: testing a cancer drug against a defined molecular target\n\nA phase 1 trial of the BCR-ABL inhibitor STI571, later known as imatinib, reported substantial antileukemic activity in chronic-phase CML after interferon treatment had failed. It provided clinical evidence for targeting a specific molecular abnormality.\n\n## Scientific scope\n\nThe 83-patient early trial was not a randomized comparison of every treatment and does not mean all cancers are cured. Earlier chemistry and disease-mechanism research, later trials and long-term resistance remain distinct work.\n\n## Reading status\n\nThis is a source-linked WRS catalogue note. A full explanatory guide and independent scientific reconstruction have not been completed for this entry. Read the identified original work for its complete narrative and arguments.\n\n## People and systems\n\nBrian J. Druker; Moshe Talpaz; Debra J. Resta; Bin Peng; Elisabeth Buchdunger; John M. Ford; Nicholas B. Lydon; Hagop Kantarjian; Renaud Capdeville; Sayuri Ohno-Jones; Charles L. Sawyers\n\nSource-paper byline retained. This is not a complete roster of a lifetime project or verified unique person identities.\n\n\n\n## Original sources\n\n- [Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia](https://doi.org/10.1056/nejm200104053441401)\n- [Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia — deposited bibliography](https://api.crossref.org/works/10.1056%2FNEJM200104053441401)\n- [Druker and colleagues: original phase 1 trial abstract](https://pubmed.ncbi.nlm.nih.gov/11287972/)\n", "summary": "A phase 1 trial of the BCR-ABL inhibitor STI571, later known as imatinib, reported substantial antileukemic activity in chronic-phase CML after interferon treatment had failed. It provided clinical evidence for targeting a specific molecular abnormality.", "title": "Imatinib: testing a cancer drug against a defined molecular target" }, "record_id": "urn:uuid:17b3b926-7126-4086-a8b9-aea21be910b4", "version": 1, "source_ref": { "record_id": "urn:uuid:17b3b926-7126-4086-a8b9-aea21be910b4", "version": 1, "content_hash": "sha256:303eca355626e9c52eb581201cdc1b4f91bf31d89c1a733982e208d0027d3444" }, "export_view": "wrs-public-editorial-view-1", "public_view_hash": "sha256:de075796c8db3b05a5726a6c0557de0515b59c18cc88de2a13b7680f220363da" }, "target": { "record_id": "urn:uuid:17b3b926-7126-4086-a8b9-aea21be910b4", "version": 1, "content_hash": "sha256:303eca355626e9c52eb581201cdc1b4f91bf31d89c1a733982e208d0027d3444" }, "published_grade": { "profile": "wrs-published-grade-1", "edition": "2026-10-28.1", "id": "imatinib-cml-trial", "entry_id": "imatinib-cml-trial", "revision": 1, "title": "Imatinib: testing a cancer drug against a defined molecular target", "context": "Targeted cancer therapy", "track": "Scoped scientific or research-capability contribution", "band": "A", "modifier": null, "status": "PROVISIONAL_EDITORIAL", "assessed_on": "2026-09-14", "evidence_cutoff": "2026-09-14", "achievement_state": "SUPPORTED_SCOPED_RESULT", "what_changed": "A phase 1 trial of the BCR-ABL inhibitor STI571, later known as imatinib, reported substantial antileukemic activity in chronic-phase CML after interferon treatment had failed. It provided clinical evidence for targeting a specific molecular abnormality.", "scope": "A phase 1 trial of the BCR-ABL inhibitor STI571, later known as imatinib, reported substantial antileukemic activity in chronic-phase CML after interferon treatment had failed. It provided clinical evidence for targeting a specific molecular abnormality. Scope limitation: The 83-patient early trial was not a randomized comparison of every treatment and does not mean all cancers are cured. Earlier chemistry and disease-mechanism research, later trials and long-term resistance remain distinct work.", "evidence_summary": "Assessment uses the catalogue-linked source evidence for the stated contribution. The 83-patient early trial was not a randomized comparison of every treatment and does not mean all cancers are cured. Earlier chemistry and disease-mechanism research, later trials and long-term resistance remain distinct work.", "references": [ { "title": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia", "url": "https://doi.org/10.1056/nejm200104053441401", "locator": "Retained catalogue source evidence; Exact DOI and deposited bibliography; content-reading scope is recorded on the accompanying sources." }, { "title": "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia — deposited bibliography", "url": "https://api.crossref.org/works/10.1056%2FNEJM200104053441401", "locator": "Retained catalogue source evidence; Retained response bytes and source byline; deposits can omit authors and reprint dates differ from original contribution dates." }, { "title": "Druker and colleagues: original phase 1 trial abstract", "url": "https://pubmed.ncbi.nlm.nih.gov/11287972/", "locator": "Retained catalogue source evidence; Abstract, trial population, phase, observed response and 11-author source roster." } ], "roles": [ { "who": "The research collaboration listed in the linked record and source byline", "credit": "SCIENCE", "did": "Collective scoped contribution. The complete recorded byline remains in the research record; this label does not collapse people into one individual." } ], "target": { "record_id": "urn:uuid:17b3b926-7126-4086-a8b9-aea21be910b4", "version": 1, "content_hash": "sha256:303eca355626e9c52eb581201cdc1b4f91bf31d89c1a733982e208d0027d3444" }, "scientific_correctness_certified": false, "independent_expert_calibration": false, "method": "PROPRIETARY", "points": "75000" }, "canonical_agent_submission": false, "scientific_verification_awarded": false, "reader_guide": null, "reading_status": "SOURCE_LINKED_NOTE" }